Benzinga Money is a reader-supported publication. We may earn a commission from the advertisers associated with this article. Read our Advertiser Discloser.
More than 10 million people globally die from cancer each year, making it the second leading cause of death behind heart disease.
Despite advancements in immunotherapy, patients are often left with limited options. Traditional treatments like chemotherapy, radiation, and surgery come with severe side effects, inconsistent success rates, and struggle to generate a strong or lasting immune response.
A new treatment with successful in-vitro test results seeks to change that. CancerVax is pioneering a novel approach that tricks the immune system into identifying and only attacking cancer cells.
CancerVax has already raised $5.6 million in prior funding and plans to begin animal testing, which is expected to be completed sometime in Q1 2026. They’re looking for new investors who want to be part of the future of cancer treatment.
Tricking the Body to Fight Cancer
Cancer is unlike other diseases because it’s not caused by foreign pathogens, which the body can easily detect and kill. Cancer cells were originally healthy cells, so it goes undetected by our immune system.
While chemotherapy and radiation can help kill the cancer cells, they also impact the healthy cells and lead to side effects that severely affect patients’ quality of life. CancerVax’s approach tricks the body into thinking the cancer cells are a foreign pathogen, such as measles, leaving the healthy cells alone.
Here’s how it works: The company’s nanoparticle-based cancer immunotherapy technology uses a novel two-step strategy to precisely detect cancer cells.
Step 1: The nanoparticle latches onto surface proteins highly expressed on cancer cells (“Marker1”)
Step 2: The nanoparticle releases a proprietary Smart mRNA payload that is conditionally activated based on cancer genetic signatures (“Marker2”)
This forces the cancer cells to produce proteins that mimic those of well-immunized diseases, or diseases that can easily be prevented with vaccinations. The immune system, already trained to fight these diseases, then rapidly eliminates the disguised cancer cells.
This innovative method leverages AI-powered detection and a two-step targeting system, providing a precise and potentially more effective treatment.
The technology was proven effective in in-vitro test studies. “This cancer specificity can be a huge leap forward to improving patient outcomes while significantly reducing harmful side effects,” Dr. Adam Grant, CancerVax’s principal scientist, said in a recent podcast interview.
Grant is a computational biologist specializing in immunotherapy who specializes in using next generation sequencing data to identify new drug targets and biomarkers of response to cancer therapeutics.
He’s part of a world-class team of experienced cancer scientists and advisors that includes Dr. George Katibah, chief scientific officer, who has a deep background in immunology and the tumor microenvironment; Sumant Ramachandra, MD, PhD, MBA, chief scientific advisor, who has worked at several pharmaceutical companies, including serving as president of Baxter Pharmaceuticals, and earlier in his career specialized in oncology, global product development, medical affairs, business development, and clinical pharmacology.
The global cancer immunotherapy market is expected to reach $231 billion by 2031, up from $83 billion in 2023, reflecting increasing demand for innovative treatment options.
CancerVax’s technology has been recognized by top cancer researchers and represents a unique opportunity to transform cancer treatment for millions of people.
They’re looking for new investors to help them accomplish that goal.
Accredited and non-accredited investors can earn shares in CancerVax with a minimum investment of $525.
Disclaimer: Please be advised that alternative investments carry a risk of monetary loss. Neither Benzinga nor its staff recommends that you buy, sell, or hold any security. We do not offer investment advice, personalized or otherwise. All information contained on this website is provided as general commentary for informative and entertainment purposes and does not constitute investment advice. Benzinga will not accept liability for any loss or damage, including without limitation to, any loss of profit, which may arise directly or indirectly from use of or reliance on this information, whether specifically stated in the above Terms of Service or otherwise. Benzinga recommends that you conduct your own due diligence and consult a certified financial professional for personalized advice about your financial situation.
